All In MedTech

Device Trial Radar · NCT03215914

Hybrid Closed Loop Insulin Delivery System in Hypoglycemia

Effect of Hybrid Closed-Loop Insulin Delivery on Glucose Counterregulation in Long Standing Type 1 Diabetes: A Proof of Concept, Mechanistic, Single-Arm Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Aug 1, 2017

Primary completion

May 31, 2022

Study completion Oct 1, 2024

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Jul 12, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 25 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Can a type 1 diabetic adult avoid low glucoses and regain hypoglycemia awareness using a hybrid closed loop insulin delivery system? Involvement is 22 months (13 visits) and includes a 4-week Screening Phase and an 18-month Intervention Phase. Participants will undergo 3 Hyperinsulinemic Clamps done at: Baseline (before starting the device and after completing the screening), 6 months (after using the device 6 months), and after using the device for 18 months. This metabolic testing will allow us to measure improvement in hypoglycemia awareness.

Conditions

  • Type1diabetes
  • Hypoglycemia Unawareness
  • Nocturnal Hypoglycemia
  • Hypoglycemia Night
  • Hypoglycemia

Interventions

  • MiniMed 670G systemDevice

    Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endogenous Glucose ProductionTime frame: After 6 months of hybrid closed-loop insulin delivery.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical and Translational Research Center, Hospital of University of Pennsylvania

    Philadelphia, Pennsylvania

  • Rodebaugh Diabetes Center, University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.